Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial

被引：26

作者：

Amerikanou, Charalampia ^{[1
]}

Kanoni, Stavroula ^{[2
]}

Kaliora, Andriana C. ^{[1
]}

Barone, Angela ^{[3
]}

Bjelan, Mladen ^{[4
]}

D'Auria, Giuseppe ^{[5
,6
]}

Gioxari, Aristea ^{[1
]}

Gosalbes, Maria Jose ^{[6
,7
,8
]}

Mouchti, Sofia ^{[3
]}

Stathopoulou, Maria G. ^{[9
]}

Soriano, Beatriz ^{[10
]}

Stojanoski, Stefan ^{[4
,11
]}

Banerjee, Rajarshi ^{[3
]}

Halabalaki, Maria ^{[12
]}

Mikropoulou, Eleni V. ^{[12
]}

Kannt, Aimo ^{[13
,14
,15
]}

Lamont, John ^{[16
]}

Llorens, Carlos ^{[10
]}

Marascio, Fernando ^{[17
]}

Marascio, Miriam ^{[17
]}

Roig, Francisco J. ^{[10
,18
]}

Smyrnioudis, Ilias ^{[19
]}

Varlamis, Iraklis ^{[20
]}

Visvikis-Siest, Sophie ^{[9
]}

Vukic, Milan ^{[21
]}

Milic, Natasa ^{[4
]}

Medic-Stojanoska, Milica ^{[4
,22
]}

Cesarini, Lucia ^{[23
]}

Campolo, Jonica ^{[24
]}

Gastaldelli, Amalia ^{[25
]}

Deloukas, Panos ^{[2
,26
]}

Trivella, Maria Giovanna ^{[24
,25
]}

Francino, M. Pilar ^{[6
,7
,8
]}

Dedoussis, George V. ^{[1
]}

机构：

[1] Harokopio Univ, Sch Hlth Sci & Educ, Dept Nutr & Dietet, Athens, Greece

[2] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London EC1M 6BQ, England

[3] Perspectum Ltd, Oxford, England

[4] Univ Novi Sad, Fac Med, Novi Sad, Serbia

[5] Fundacio Foment Invest Sanitaria & Biomed Comnita, Sequencing & Bioinformat Serv, Comunitat Valenciana FISABIO Salut Publ, Avda Catalunya 21, Valencia 46020, Spain

[6] CIBER Epidmiol & Salud Publ, Av Monforte Lemos 3-5, Madrid 28029, Spain

[7] Univ Valencia, Joint Res Unit Genom & Hlth Fundacio Foment Inves, CSIC, Avda Catalunya 21, Valencia 46020, Spain

[8] Univ Valencia, Inst Biol Integrat Sistemes, Avda Catalunya 21, Valencia 46020, Spain

[9] Univ Loraine, UMR INSERM U1122, PCV, IGE, Nancy, France

[10] Univ Valencia, Biotechvana, Parc Cient, Valencia, Spain

[11] Oncol Inst Vojvodina, Ctr Imaging Diagnost, Sremska Kamenica, Serbia

[12] Natl & Kapodistrian Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, Athens, Greece

[13] Sanofi Res & Dev, Ind Pk Hoechst, D-65926 Frankfurt, Germany

[14] Goethe Univ Frankfurt, Inst Clin Pharmacol, D-60590 Frankfurt, Germany

[15] Fraunhofer Inst Translat Med & Pharmacol ITMP, D-60596 Frankfurt, Germany

[16] Randox Labs Ltd, Co Antrim, Northern Irelan, England

[17] Marascio Fernando, Intervideo, I-88100 Catanzaro, CZ, Italy

[18] Univ San Jorge, Fac Ciencias Salud, Zaragoza 50830, Spain

[19] Chios Mast Gum Growers Assoc, Chios, Greece

[20] Harokopio Univ, Dept Informat & Telemat, Athens, Greece

[21] Univ East Sarajevo, Fac Technol Zvornik, Dept Food Technol, Zvornik 75400, Bosnia & Herceg

[22] Clin Ctr Vojvodina, Clin Endocrinol Diabet & Metab Dis, Novi Sad, Serbia

[23] Niguarda Ca Grande Hosp Milan, Div Hepatol & Gastroenterol, Milan, Italy

[24] CNR, Inst Clin Physiol, Milan, Italy

[25] CNR, Inst Clin Physiol, Cardiometabol Risk Unit, Pisa, Italy

[26] Queen Mary Univ London, Ctr Genom Hlth, Life Sci, London, England

来源：

MOLECULAR NUTRITION & FOOD RESEARCH | 2021年 / 65卷 / 10期

关键词：

Mastiha; metabolomics; microbiota dysbiosis; MRI; NAFLD; NASH; MULTIPARAMETRIC MAGNETIC-RESONANCE; FATTY LIVER-DISEASE; GUT MICROBIOTA; FIBROSIS; DATABASE; GLUCOSE; IMMUNE; SCORE;

D O I：

10.1002/mnfr.202001178

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Scope Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with poor therapeutic strategies. Mastiha possesses antioxidant/anti-inflammatory and lipid-lowering properties. The authors investigate the effectiveness of Mastiha as a nonpharmacological intervention in NAFLD. Methods and Results Ninety-eight patients with NAFLD in three countries (Greece, Italy, Serbia) are randomly allocated to either Mastiha or Placebo for 6 months, as part of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The authors assess NAFLD severity via magnetic resonance imaging (MRI) scanning and LiverMultiScan technique and evaluate the effectiveness of Mastiha through medical, anthropometric, biochemical, metabolomic, and microbiota assessment. Mastiha is not superior to Placebo on changes in iron-corrected T1 (cT1) and Liver Inflammation Fibrosis score (LIF) in entire patient population; however, after BMI stratification (BMI <= 35 kg m(-2) and BMI > 35 kg m(-2)), severely obese patients show an improvement in cT1 and LIF in Mastiha versus Placebo. Mastiha increases dissimilarity of gut microbiota, as shown by the Bray-Curtis index, downregulates Flavonifractor, a known inflammatory taxon and decreases Lysophosphatidylcholines-(LysoPC) 18:1, Lysophosphatidylethanolamines-(LysoPE) 18:1, and cholic acid compared to Placebo. Conclusion Mastiha supplementation improves microbiota dysbiosis and lipid metabolite levels in patients with NAFLD, although it reduces parameters of liver inflammation/fibrosis only in severely obese patients.

引用

页数：10

共 46 条

[31] Antioxidant and Anti-Inflammatory Properties of Mastiha: A Review of Preclinical and Clinical Studies [J].

Papada, Efstathia ;

Kaliora, Andriana C. .

ANTIOXIDANTS, 2019, 8 (07)

[32] In vitro and in vivo activities of chios mastic gum extracts and constituents against Helicobacter pylori [J].

Paraschos, Sotirios ;

Magiatis, Prokopios ;

Mitakou, Sofia ;

Petraki, Kalliopi ;

Kalliaropoulos, Antonios ;

Maragkoudakis, Petros ;

Mentis, Andreas ;

Sgouras, Dionyssios ;

Skaltsounis, Alexios-Leandros .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (02) :551-559

[33] Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease [J].

Pavlides, Michael ;

Banerjee, Rajarshi ;

Sellwood, Joanne ;

Kelly, Catherine J. ;

Robson, Matthew D. ;

Booth, Jonathan C. ;

Collier, Jane ;

Neubauer, Stefan ;

Barnes, Eleanor .

JOURNAL OF HEPATOLOGY, 2016, 64 (02) :308-315

[34] Noninvasive Diagnosis of NAFLD and NASH [J].

Piazzolla, Valeria Annarita ;

Mangia, Alessandra .

CELLS, 2020, 9 (04)

[35] MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data [J].

Pluskal, Tomas ;

Castillo, Sandra ;

Villar-Briones, Alejandro ;

Oresic, Matej .

BMC BIOINFORMATICS, 2010, 11

[36] The SILVA ribosomal RNA gene database project: improved data processing and web-based tools [J].

Quast, Christian ;

Pruesse, Elmar ;

Yilmaz, Pelin ;

Gerken, Jan ;

Schweer, Timmy ;

Yarza, Pablo ;

Peplies, Joerg ;

Gloeckner, Frank Oliver .

NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) :D590-D596

[37] Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis [J].

Quesada-Vazquez, Sergio ;

Aragones, Gerard ;

Del Bas, Josep M. ;

Escote, Xavier .

CELLS, 2020, 9 (01)

[38] Chemometric approaches to improve PLSDA model outcome for predicting human non-alcoholic fatty liver disease using UPLC-MS as a metabolic profiling tool [J].

Quintas, Guillermo ;

Portillo, Nuria ;

Carlos Garcia-Canaveras, Juan ;

Vicente Castell, Jose ;

Ferrer, Alberto ;

Lahoz, Agustin .

METABOLOMICS, 2012, 8 (01) :86-98

[39] Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial [J].

Rahmani, Sepideh ;

Asgary, Sedigheh ;

Askari, Gholamreza ;

Keshvari, Mahtab ;

Hatamipour, Mahdi ;

Feizi, Awat ;

Sahebkar, Amirhossein .

PHYTOTHERAPY RESEARCH, 2016, 30 (09) :1540-1548

[40]

Scorletti E, 2020, GASTROENTEROLOGY, V158, P1597, DOI 10.1053/j.gastro.2020.01.031

← 1 2 3 4 5 →